Literature DB >> 20966911

Subclinical regional left ventricular dysfunction in obese patients with and without hypertension or hypertrophy.

José L F Santos1, Vera M C Salemi, Michael H Picard, Charles Mady, Otávio R Coelho.   

Abstract

We investigated the impact of obesity on the abnormalities of systolic and diastolic regional left ventricular (LV) function in patients with or without hypertension or hypertrophy, and without heart failure. We studied 120 individuals divided into 6 groups of 20 patients (42 ± 6 years, 60 females) using standard and pulsed-wave tissue Doppler imaging (TDI) echocardiography, and heterogeneity index (HI): nonobese (I: no hypertension, no hypertrophy, control group; II: hypertension, no hypertrophy; III: hypertension and hypertrophy) and obese (IV: no hypertension, no hypertrophy; V: hypertension, no hypertrophy; VI: hypertension and hypertrophy). The criterion for obesity was BMI ≥30 kg/m2, for hypertension was blood pressure ≥ 140/90 mm Hg, for hypertrophy in nonobese was LV mass/body surface area (BSA) >134 g/m(2) (men) and >110 mg/m2 (women), and in obese was LV mass/height(2.7) >50 (men) and >40 (women). Obese groups had normal LV ejection fraction compared with nonobese groups, but decreased longitudinal and radial systolic myocardial peak velocities (S'), and early diastolic myocardial peak velocity (E'). Also, a great variability of E' and late diastolic myocardial peak velocity (A') from the longitudinal basal region was observed in obese groups (E'basal nonobese: 11 ± 7 vs. obese 19 ± 11, P < 0.001, A'basal nonobese: 7 ± 4 vs. obese 11 ± 7, P < 0.001). Our findings were more evident when comparing groups IV with V and VI, with the latter having concentric hypertrophy and obvious segmental systolic and diastolic dysfunctions. Subclinical myocardial alterations and increased variability of the velocities were observed in obese groups, especially with hypertension and hypertrophy, reflecting impaired regional LV relaxation, segmental atrial, and systolic dysfunctions.

Entities:  

Mesh:

Year:  2010        PMID: 20966911     DOI: 10.1038/oby.2010.253

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  8 in total

Review 1.  The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.

Authors:  Tina Thethi; Masumi Kamiyama; Hiroyuki Kobori
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

2.  Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats.

Authors:  Annayya R Aroor; James R Sowers; Shawn B Bender; Ravi Nistala; Mona Garro; Irina Mugerfeld; Melvin R Hayden; Megan S Johnson; Muhammad Salam; Adam Whaley-Connell; Vincent G Demarco
Journal:  Endocrinology       Date:  2013-05-07       Impact factor: 4.736

3.  Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice.

Authors:  Vincent G Demarco; David A Ford; Erik J Henriksen; Annayya R Aroor; Megan S Johnson; Javad Habibi; Lixin Ma; Ming Yang; Carolyn J Albert; John W Lally; Caleb A Ford; Mujalin Prasannarong; Melvin R Hayden; Adam T Whaley-Connell; James R Sowers
Journal:  Endocrinology       Date:  2012-11-09       Impact factor: 4.736

Review 4.  Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.

Authors:  Annayya R Aroor; James R Sowers; Guanghong Jia; Vincent G DeMarco
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-15       Impact factor: 4.733

5.  Changes of myocardial lipidomics profiling in a rat model of diabetic cardiomyopathy using UPLC/Q-TOF/MS analysis.

Authors:  Shifen Dong; Rong Zhang; Yaoyue Liang; Jiachen Shi; Jiajia Li; Fei Shang; Xuezhou Mao; Jianning Sun
Journal:  Diabetol Metab Syndr       Date:  2017-07-20       Impact factor: 3.320

Review 6.  The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.

Authors:  Annayya R Aroor; Camila Manrique-Acevedo; Vincent G DeMarco
Journal:  Cardiovasc Diabetol       Date:  2018-04-18       Impact factor: 9.951

7.  Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.

Authors:  Annayya R Aroor; Srinivas Mummidi; Juan Carlos Lopez-Alvarenga; Nitin Das; Javad Habibi; Guanghong Jia; Guido Lastra; Bysani Chandrasekar; Vincent G DeMarco
Journal:  Cardiovasc Diabetol       Date:  2021-04-21       Impact factor: 9.951

8.  Relationship of body fat and left ventricular hypertrophy with the risk of all-cause death in patients with coronary artery disease.

Authors:  Bao-Tao Huang; Lu Yang; Bo-Sen Yang; Fang-Yang Huang; Qian-Feng Xiao; Xiao-Bo Pu; Yong Peng; Mao Chen
Journal:  J Geriatr Cardiol       Date:  2022-03-28       Impact factor: 3.327

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.